Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2. San Antonio Breast Cancer Symposium attendees this week considered evidence that bevacizumab…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 3. Today at the San Antonio Breast Cancer Symposium, real world economics shared…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 3. Participants in the San Antonio Breast Cancer Symposium today heard evidence that…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 4. In one of our final reports from the San Antonio Breast Cancer…
Join us for complete coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2. Several papers describing research into the screening and management of breast cancer…
Join us for complete coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 2. Several papers describing research into the screening and management of breast cancer…
Join us for continued coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 1. The long-awaited AZURE Trial – The Carry-Over Effect of Adjuvant Zoledronic Acid:…
Join us for complete coverage of the 33rd CTRC-AACR San Antonio Breast Cancer Symposium, Day 1. Several papers describing research into the screening and management of breast cancer…
NEW YORK (Reuters Health) – Brachytherapy is a viable option for prostate cancer patients 60 and younger, the authors of a new report in BJUI conclude. “Prostate cancer…
This week, the 2010 CTRC-AACR San Antonio Breast Cancer Symposium kicks off. The Doctor’s Channel provides leading news coverage of all the late breaking trial and study data…
